Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy is organized by PVI, PeerView Institute for Medical Education, Penn State College of Medicine.

Release Date: July 27, 2020
Expiration Date: July 26, 2021

Accreditation:
Physicians
The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer.

Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations
• Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings
• Recommend patient-appropriate novel therapeutics for the management of bladder cancer
• Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer